{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:11:13Z","timestamp":1788862273806,"version":"build-2803163510"},"reference-count":274,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["1SB1NS135733-01"],"award-info":[{"award-number":["1SB1NS135733-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["2R44NS107079-02A1"],"award-info":[{"award-number":["2R44NS107079-02A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"NIEHS","doi-asserted-by":"publisher","award":["1R44ES031038-01"],"award-info":[{"award-number":["1R44ES031038-01"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH NIGMS","doi-asserted-by":"publisher","award":["R44GM122196-02A1"],"award-info":[{"award-number":["R44GM122196-02A1"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["1R43DA055419-01"],"award-info":[{"award-number":["1R43DA055419-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.neurot.2025.e00624","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:31:23Z","timestamp":1750174283000},"page":"e00624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Applications of artificial intelligence in drug discovery for neurological diseases"],"prefix":"10.1016","volume":"22","author":[{"given":"Sean","family":"Ekins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00624_bib2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.0511","article-title":"Comparison of research spending on new drug approvals by the national Institutes of health vs the pharmaceutical industry, 2010-2019","volume":"4","author":"Galkina Cleary","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40545-023-00590-9","article-title":"Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach","volume":"16","author":"Henderson","year":"2023","journal-title":"J Pharm Policy Pract"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104291","article-title":"Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006\u20132022)","volume":"30","author":"Schuhmacher","year":"2025","journal-title":"Drug Discov Today"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00624_bib6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrd2094","article-title":"Drug development for CNS disorders: strategies for balancing risk and reducing attrition","volume":"6","author":"Pangalos","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00624_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163107","article-title":"Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep","volume":"132","author":"Nelvagal","year":"2022","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00624_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41563-019-0338-z","article-title":"Exploiting machine learning for end-to-end drug discovery and development","volume":"18","author":"Ekins","year":"2019","journal-title":"Nat Mater"},{"key":"10.1016\/j.neurot.2025.e00624_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CLEP.S37929","article-title":"Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences","volume":"6","author":"Mielke","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5607\/en.2013.22.2.84","article-title":"An update of animal models of Alzheimer disease with a reevaluation of plaque depositions","volume":"22","author":"Lee","year":"2013","journal-title":"Exp Neurobiol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bcp.12621","article-title":"Emerging drug targets for Abeta and tau in Alzheimer's disease: a systematic review","volume":"80","author":"West","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00624_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"10053","key":"10.1016\/j.neurot.2025.e00624_bib13","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Disease","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00624_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/toxsci\/kfaa167","article-title":"Can we panelize seizure?","volume":"179","author":"Roberts","year":"2021","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.neurot.2025.e00624_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.vascn.2016.06.001","article-title":"Safety pharmacology investigations on the nervous system: an industry survey","volume":"81","author":"Authier","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.neurot.2025.e00624_bib18","first-page":"227","article-title":"The hidden costs of the opioid crisis and the implications for financial management in the public sector","volume":"1","author":"Ropero-Miller","year":"2019","journal-title":"Forensic Sci Int"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ana.24897","article-title":"The burden of neurological disease in the United States: a summary report and call to action","volume":"81","author":"Gooch","year":"2017","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/ci300535x","article-title":"Visualization and virtual screening of the chemical universe database GDB-17","volume":"53","author":"Ruddigkeit","year":"2013","journal-title":"J Chem Inf Model"},{"issue":"7873","key":"10.1016\/j.neurot.2025.e00624_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"32","key":"10.1016\/j.neurot.2025.e00624_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn1524","article-title":"AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine-associated receptor 1","volume":"10","author":"Diaz-Holguin","year":"2024","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer's disease: targeting the cholinergic system","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Curr Neuropharmacol"},{"issue":"17","key":"10.1016\/j.neurot.2025.e00624_bib24","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.2174\/092986710791111198","article-title":"Structure-activity relationship of quaternary acetylcholinesterase inhibitors - outlook for early myasthenia gravis treatment","volume":"17","author":"Komloova","year":"2010","journal-title":"Curr Med Chem"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00624_bib25","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1007\/s00726-016-2310-4","article-title":"Evaluating Fmoc-amino acids as selective inhibitors of butyrylcholinesterase","volume":"48","author":"Gonzalez","year":"2016","journal-title":"Amino Acids"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1389557013406864","article-title":"Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease","volume":"1","author":"Castro","year":"2001","journal-title":"Mini Rev Med Chem"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/0929867003375254","article-title":"Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors","volume":"7","author":"Kaur","year":"2000","journal-title":"Curr Med Chem"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/jm950704x","article-title":"A comparative molecular field analysis study of N-benzylpiperidines as acetylcholinesterase inhibitors","volume":"39","author":"Tong","year":"1996","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0223-5234(00)00108-2","article-title":"Validation of protein-based alignment in 3D quantitative structure-activity relationships with CoMFA models","volume":"35","author":"Golbraikh","year":"2000","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/toxsci\/63.2.223","article-title":"Prediction of organophosphorus acetylcholinesterase inhibition using three-dimensional quantitative structure-activity relationship (3D-QSAR) methods","volume":"63","author":"El","year":"2001","journal-title":"Toxicol Sci"},{"issue":"22","key":"10.1016\/j.neurot.2025.e00624_bib31","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1021\/jm0497141","article-title":"A comparison of methods for modeling quantitative structure-activity relationships","volume":"47","author":"Sutherland","year":"2004","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1747-0285.2006.00435.x","article-title":"Ensembles of Bayesian-regularized genetic neural networks for modeling of acetylcholinesterase inhibition by huprines","volume":"68","author":"Fernandez","year":"2006","journal-title":"Chem Biol Drug Des"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib33","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.bmcl.2006.11.022","article-title":"Quantitative structure-activity relationship (QSAR) of tacrine derivatives against acetylcholinesterase (AChE) activity using variable selections","volume":"17","author":"Jung","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.neurot.2025.e00624_bib34","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1021\/ci800009u","article-title":"SAMFA: simplifying molecular descriptors for 3D-QSAR","volume":"48","author":"Manchester","year":"2008","journal-title":"J Chem Inf Model"},{"issue":"24","key":"10.1016\/j.neurot.2025.e00624_bib35","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1016\/j.bmcl.2006.09.030","article-title":"3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA","volume":"16","author":"Akula","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00624_bib36","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1080\/07391102.2018.1468281","article-title":"Dynamic structure based pharmacophore modeling of the Acetylcholinesterase reveals several potential inhibitors","volume":"37","author":"Shiri","year":"2019","journal-title":"J Biomol Struct Dyn"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00624_bib37","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1007\/s11095-009-9937-8","article-title":"Predicting inhibitors of acetylcholinesterase by regression and classification machine learning approaches with combinations of molecular descriptors","volume":"26","author":"Chekmarev","year":"2009","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1386207320666171123201910","article-title":"Identification of human acetylcholinesterase inhibitors from the constituents of EGb761 by modeling docking and molecular dynamics simulations","volume":"21","author":"Zhang","year":"2018","journal-title":"Comb Chem High Throughput Screen"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1871527317666180115162422","article-title":"In silico structure-based identification of novel acetylcholinesterase inhibitors against Alzheimer's disease","volume":"17","author":"Iman","year":"2018","journal-title":"CNS Neurol Disord: Drug Targets"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00624_bib40","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.bmcl.2016.01.080","article-title":"In silico to in vitro screening of hydroxypyridinones as acetylcholinesterase inhibitors","volume":"26","author":"Telpoukhovskaia","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00624_bib41","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1021\/acs.jcim.5b00449","article-title":"Discovering new acetylcholinesterase inhibitors by mining the Buzhongyiqi decoction recipe data","volume":"55","author":"Cui","year":"2015","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.neurot.2025.e00624_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtbi.2018.09.030","article-title":"MIA-QSAR based model for bioactivity prediction of flavonoid derivatives as acetylcholinesterase inhibitors","volume":"459","author":"Muthukumaran","year":"2018","journal-title":"J Theor Biol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33354-6","article-title":"Identification of novel acetylcholinesterase inhibitors designed by pharmacophore-based virtual screening, molecular docking and bioassay","volume":"8","author":"Jang","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00624_bib44","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4155\/fmc-2017-0201","article-title":"Discovery of novel dual acetylcholinesterase inhibitors with antifibrillogenic activity related to Alzheimer's disease","volume":"10","author":"de Almeida","year":"2018","journal-title":"Future Med Chem"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00624_bib45","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10822-019-00202-2","article-title":"Discovery of new multifunctional selective acetylcholinesterase inhibitors: structure-based virtual screening and biological evaluation","volume":"33","author":"Jiang","year":"2019","journal-title":"J Comput Aided Mol Des"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00624_bib46","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acs.chemrestox.0c00466","article-title":"The antiviral drug tilorone is a potent and selective inhibitor of acetylcholinesterase","volume":"34","author":"Vignaux","year":"2021","journal-title":"Chem Res Toxicol"},{"issue":"D1","key":"10.1016\/j.neurot.2025.e00624_bib47","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"suppl_1","key":"10.1016\/j.neurot.2025.e00624_bib48","first-page":"D198","article-title":"BindingDB: a web-accessible database of experimentally determined protein\u2013ligand binding affinities","volume":"35","author":"Liu","year":"2006","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib49","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1021\/acs.chemrestox.2c00283","article-title":"Validation of acetylcholinesterase inhibition machine learning models for multiple species","volume":"36","author":"Vignaux","year":"2023","journal-title":"Chem Res Toxicol"},{"issue":"16","key":"10.1016\/j.neurot.2025.e00624_bib50","doi-asserted-by":"crossref","first-page":"8749","DOI":"10.1021\/acs.jmedchem.9b00959","article-title":"Pushing the boundaries of molecular representation for drug discovery with the graph attention mechanism","volume":"63","author":"Xiong","year":"2020","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0021-9258(18)73318-8","article-title":"Cholinesterases in the blood of man","volume":"133","author":"Alles","year":"1940","journal-title":"J Biol Chem"},{"issue":"2539","key":"10.1016\/j.neurot.2025.e00624_bib52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1126\/science.98.2539.201.b","article-title":"On the type of cholinesterase present in brain tissue","volume":"98","author":"Mendel","year":"1943","journal-title":"Science"},{"key":"10.1016\/j.neurot.2025.e00624_bib53","first-page":"426","article-title":"The biology of cholinesterases","volume":"36","author":"Silver","year":"1974","journal-title":"Front Biol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrn1035","article-title":"Neurobiology of butyrylcholinesterase","volume":"4","author":"Darvesh","year":"2003","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib55","first-page":"52","article-title":"Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene","volume":"58","author":"Primo-Parmo","year":"1996","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.neurot.2025.e00624_bib56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7150\/jbm.26783","article-title":"Current therapeutic targets for Alzheimer's disease","volume":"3","author":"Chaudhary","year":"2018","journal-title":"J Biomed"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2174\/157340808786733631","article-title":"Cholinesterases and cholinesterase inhibitors","volume":"4","author":"Stepankova","year":"2008","journal-title":"Curr Enzym Inhib"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00624_bib58","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0736-5748(90)90051-3","article-title":"Non-specific cholinesterase activity of the developing peripheral nerves and its possible function in cells in intimate contact with growing axons of chick embryo","volume":"8","author":"Dubovy","year":"1990","journal-title":"Int J Dev Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00712798","article-title":"Cholinesterases during development of the avian nervous system","volume":"11","author":"Layer","year":"1991","journal-title":"Cell Mol Neurobiol"},{"issue":"1-2","key":"10.1016\/j.neurot.2025.e00624_bib60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0165-3806(88)90168-X","article-title":"Development of 'non-specific' cholinesterase-containing neurons in the dorsal thalamus of the rat","volume":"469","author":"Robertson","year":"1988","journal-title":"Brain Res"},{"issue":"5882","key":"10.1016\/j.neurot.2025.e00624_bib61","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/299439a0","article-title":"Pseudocholinesterase staining in the primary visual pathway of the macaque monkey","volume":"299","author":"Graybiel","year":"1982","journal-title":"Nature"},{"issue":"8369","key":"10.1016\/j.neurot.2025.e00624_bib62","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(84)90116-8","article-title":"Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease","volume":"1","author":"Arendt","year":"1984","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2990.1978.tb00545.x","article-title":"Changes in brain cholinesterases in senile dementia of Alzheimer type","volume":"4","author":"Perry","year":"1978","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.neurot.2025.e00624_bib64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12031-009-9269-5","article-title":"Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy","volume":"40","author":"Maelicke","year":"2010","journal-title":"J Mol Neurosci"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00624_bib65","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","article-title":"Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease","volume":"271","author":"Watkins","year":"1994","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib66","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pharmthera.2011.12.002","article-title":"Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors","volume":"134","author":"Tayeb","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neurot.2025.e00624_bib67","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejmech.2017.03.062","article-title":"Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease","volume":"132","author":"Li","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib68","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/0006-291X(92)90212-4","article-title":"A computer model of glycosylated human butyrylcholinesterase","volume":"189","author":"Millard","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"issue":"42","key":"10.1016\/j.neurot.2025.e00624_bib69","doi-asserted-by":"crossref","first-page":"41141","DOI":"10.1074\/jbc.M210241200","article-title":"Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products","volume":"278","author":"Nicolet","year":"2003","journal-title":"J Biol Chem"},{"issue":"48","key":"10.1016\/j.neurot.2025.e00624_bib70","doi-asserted-by":"crossref","first-page":"14642","DOI":"10.1021\/bi971425+","article-title":"Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase","volume":"36","author":"Saxena","year":"1997","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00624_bib71","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1021\/acs.jcim.4c00397","article-title":"Sequential contrastive and deep learning models to identify selective butyrylcholinesterase inhibitors","volume":"64","author":"Ozalp","year":"2024","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.neurot.2025.e00624_bib72","series-title":"International Conference on Machine Learning","article-title":"A simple framework for contrastive learning of visual representations","year":"2020"},{"key":"10.1016\/j.neurot.2025.e00624_bib73","series-title":"Proceedings of the IEEE\/CVF Conference on Computer Vision and Pattern Recognition","article-title":"Momentum contrast for unsupervised visual representation learning","year":"2020"},{"key":"10.1016\/j.neurot.2025.e00624_bib74","first-page":"18661","article-title":"Supervised contrastive learning","volume":"33","author":"Khosla","year":"2020","journal-title":"Adv Neural Inf Process Syst"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41392-023-01427-2","article-title":"G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders","volume":"8","author":"Wong","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00624_bib76","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/1535370221993422","article-title":"Trends in application of advancing computational approaches in GPCR ligand discovery","volume":"246","author":"Zhu","year":"2021","journal-title":"Exp Biol Med"},{"issue":"6301","key":"10.1016\/j.neurot.2025.e00624_bib77","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.aag2590","article-title":"How neuroinflammation contributes to neurodegeneration","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2011.06.008","article-title":"Targeting chemokine receptors in chronic inflammatory diseases: an extensive review","volume":"133","author":"Koelink","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib79","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.brainresrev.2004.07.021","article-title":"Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases","volume":"48","author":"Cartier","year":"2005","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.neurot.2025.e00624_bib80","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3389\/fneur.2019.01391","article-title":"Expression of cytokines and chemokines as predictors of stroke outcomes in acute ischemic stroke","volume":"10","author":"Martha","year":"2019","journal-title":"Front Neurol"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00624_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28155766","article-title":"Targeting members of the chemokine family as a novel approach to treating neuropathic pain","volume":"28","author":"Pawlik","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.molpha.2024.100010","article-title":"Repurposing lapatinib as a triple antagonist of chemokine receptors 3, 4, and 5","volume":"107","author":"Lane","year":"2025","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00624_bib83","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.cell.2019.01.044","article-title":"CCR5 is a therapeutic target for recovery after stroke and traumatic brain injury","volume":"176","author":"Joy","year":"2019","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00624_bib84","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/bph.15005","article-title":"Update of P2Y receptor pharmacology: IUPHAR Review 27","volume":"177","author":"Jacobson","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"7139","key":"10.1016\/j.neurot.2025.e00624_bib85","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/nature05704","article-title":"UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis","volume":"446","author":"Koizumi","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2025.e00624_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114419","article-title":"The role of P2Y receptors in regulating immunity and metabolism","volume":"187","author":"Lovaszi","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00624_bib87","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.neuron.2024.03.017","article-title":"Microglial P2Y(6) calcium signaling promotes phagocytosis and shapes neuroimmune responses in epileptogenesis","volume":"112","author":"Umpierre","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2025.e00624_bib88","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fncel.2019.00476","article-title":"P2Y6 and P2X7 receptor antagonism exerts neuroprotective\/neuroregenerative effects in an animal model of Parkinson's disease","volume":"13","author":"Oliveira-Giacomelli","year":"2019","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12974-021-02280-2","article-title":"Inflammatory neuronal loss in the substantia nigra induced by systemic lipopolysaccharide is prevented by knockout of the P2Y(6) receptor in mice","volume":"18","author":"Milde","year":"2021","journal-title":"J Neuroinflammation"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib90","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1164\/rccm.201011-1762OC","article-title":"Purinergic receptor type 6 contributes to airway inflammation and remodeling in experimental allergic airway inflammation","volume":"184","author":"Vieira","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.neurot.2025.e00624_bib91","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fimmu.2017.01028","article-title":"P2Y(6) receptor activation promotes inflammation and tissue remodeling in pulmonary fibrosis","volume":"8","author":"Muller","year":"2017","journal-title":"Front Immunol"},{"issue":"48","key":"10.1016\/j.neurot.2025.e00624_bib92","doi-asserted-by":"crossref","first-page":"30763","DOI":"10.1073\/pnas.2006578117","article-title":"Lack of adipocyte purinergic P2Y(6) receptor greatly improves whole body glucose homeostasis","volume":"117","author":"Jain","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib93","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2020-320937","article-title":"NTPDase8 protects mice from intestinal inflammation by limiting P2Y(6) receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD","volume":"71","author":"Salem","year":"2022","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib94","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.drudis.2019.12.015","article-title":"The role of P2Y(6)R in cardiovascular diseases and recent development of P2Y(6)R antagonists","volume":"25","author":"Zhou","year":"2020","journal-title":"Drug Discov Today"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00624_bib95","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1021\/jm100287t","article-title":"Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications","volume":"53","author":"Maruoka","year":"2010","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib96","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1021\/jm901450d","article-title":"5-OMe-UDP is a potent and selective P2Y(6)-receptor agonist","volume":"53","author":"Ginsburg-Shmuel","year":"2010","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.neurot.2025.e00624_bib97","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1016\/j.bmc.2012.07.042","article-title":"UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety","volume":"20","author":"Ginsburg-Shmuel","year":"2012","journal-title":"Bioorg Med Chem"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00624_bib98","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1039\/C7MD00397H","article-title":"Pyrimidine nucleotides containing a (S)-Methanocarba ring as P2Y(6) receptor agonists","volume":"8","author":"Toti","year":"2017","journal-title":"Medchemcomm"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00624_bib99","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.bcp.2004.01.011","article-title":"Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors","volume":"67","author":"Mamedova","year":"2004","journal-title":"Biochem Pharmacol"},{"issue":"716","key":"10.1016\/j.neurot.2025.e00624_bib100","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abj0644","article-title":"Redox-dependent internalization of the purinergic P2Y(6) receptor limits colitis progression","volume":"15","author":"Nishiyama","year":"2022","journal-title":"Sci Signal"},{"key":"10.1016\/j.neurot.2025.e00624_bib101","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.lfs.2017.05.017","article-title":"Identification of novel selective P2Y(6) receptor antagonists by high-throughput screening assay","volume":"180","author":"Ito","year":"2017","journal-title":"Life Sci"},{"key":"10.1016\/j.neurot.2025.e00624_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128981","article-title":"Synthesis and pharmacological characterization of multiply substituted 2H-chromene derivatives as P2Y(6) receptor antagonists","volume":"75","author":"Jung","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00624_bib103","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1021\/acs.jmedchem.3c00210","article-title":"Discovery of selective P2Y(6)R antagonists with high affinity and in vivo efficacy for inflammatory disease therapy","volume":"66","author":"Zhu","year":"2023","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00624_bib104","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s11302-024-10003-4","article-title":"Machine learning-aided search for ligands of P2Y(6) and other P2Y receptors","volume":"20","author":"Puhl","year":"2024","journal-title":"Purinergic Signal"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib105","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: the state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00624_bib106","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tips.2016.02.006","article-title":"Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects?","volume":"37","author":"Borea","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.neurot.2025.e00624_bib107","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fncel.2019.00124","article-title":"Historical and current adenosine receptor agonists in preclinical and clinical development","volume":"13","author":"Jacobson","year":"2019","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030785","article-title":"Focusing on adenosine receptors as a potential targeted therapy in human diseases","volume":"9","author":"Effendi","year":"2020","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00624_bib109","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1523\/JNEUROSCI.5066-06.2007","article-title":"Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study","volume":"27","author":"Elmenhorst","year":"2007","journal-title":"J Neurosci"},{"issue":"193","key":"10.1016\/j.neurot.2025.e00624_bib110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/978-3-540-89615-9_17","article-title":"Adenosine receptors and neurological disease: neuroprotection and neurodegeneration","author":"Stone","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00624_bib111","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3389\/fphar.2017.00985","article-title":"The role of adenosine receptors in psychostimulant addiction","volume":"8","author":"Ballesteros-Y\u00e1\u00f1ez","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00624_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.920643","article-title":"Machine learning for discovery of new ADORA modulators","volume":"13","author":"Puhl","year":"2022","journal-title":"Front Pharmacol"},{"issue":"17","key":"10.1016\/j.neurot.2025.e00624_bib113","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.2174\/1568026620666200516153136","article-title":"Glycogen synthase kinase 3 (GSK3): its role and inhibitors","volume":"20","author":"Wadhwa","year":"2020","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.neurot.2025.e00624_bib114","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11357-019-00085-z","article-title":"An expanding GSK3 network: implications for aging research","volume":"41","author":"Souder","year":"2019","journal-title":"Geroscience"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00624_bib116","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.celrep.2018.04.010","article-title":"Inhibition of Gsk3b reduces Nfkb1 signaling and rescues synaptic activity to improve the Rett syndrome phenotype in mecp2-knockout mice","volume":"23","author":"Jorge-Torres","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.neurot.2025.e00624_bib117","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.nbd.2015.06.018","article-title":"Inhibition of GSK3beta rescues hippocampal development and learning in a mouse model of CDKL5 disorder","volume":"82","author":"Fuchs","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib118","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neulet.2006.09.026","article-title":"Age-related changes in glycogen synthase kinase 3beta (GSK3beta) immunoreactivity in the central nervous system of rats","volume":"409","author":"Lee","year":"2006","journal-title":"Neurosci Lett"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib119","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cellsig.2008.10.014","article-title":"Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity","volume":"21","author":"Yuskaitis","year":"2009","journal-title":"Cell Signal"},{"key":"10.1016\/j.neurot.2025.e00624_bib120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fncel.2020.00209","article-title":"Glia crosstalk in neuroinflammatory diseases","volume":"14","author":"Bernaus","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"27","key":"10.1016\/j.neurot.2025.e00624_bib121","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.2174\/0929867329666220216113517","article-title":"Glycogen synthase kinase 3\u03b2 involvement in neuroinflammation and neurodegenerative diseases","volume":"29","author":"Gianferrara","year":"2022","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.neurot.2025.e00624_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2012.00001","article-title":"GSK-3 and Wnt signaling in neurogenesis and bipolar disorder","volume":"5","author":"Valvezan","year":"2012","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2025.e00624_bib123","article-title":"Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward","volume":"14","author":"Arciniegas Ruiz","year":"2021","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib124","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2990.2006.00795.x","article-title":"Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration","volume":"33","author":"Leroy","year":"2007","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib125","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00005072-199701000-00007","article-title":"Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain","volume":"56","author":"Pei","year":"1997","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1-2","key":"10.1016\/j.neurot.2025.e00624_bib126","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0304-3940(92)90839-Y","article-title":"Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments","volume":"148","author":"Ishiguro","year":"1992","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib127","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0304-3940(92)90774-2","article-title":"Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase","volume":"147","author":"Hanger","year":"1992","journal-title":"Neurosci Lett"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00624_bib128","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0960-9822(00)00246-3","article-title":"Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells","volume":"4","author":"Lovestone","year":"1994","journal-title":"Curr Biol"},{"key":"10.1016\/j.neurot.2025.e00624_bib129","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neurobiolaging.2017.03.031","article-title":"Amyloid precursor protein reduction enhances the formation of neurofibrillary tangles in a mutant tau transgenic mouse model","volume":"55","author":"Vanden Dries","year":"2017","journal-title":"Neurobiol Aging"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00624_bib130","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1471-4159.2006.04139.x","article-title":"Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert","volume":"99","author":"Engel","year":"2006","journal-title":"J Neurochem"},{"issue":"21","key":"10.1016\/j.neurot.2025.e00624_bib131","doi-asserted-by":"crossref","first-page":"15823","DOI":"10.1074\/jbc.M610708200","article-title":"GSK3beta activity modifies the localization and function of presenilin 1","volume":"282","author":"Uemura","year":"2007","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib132","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI64516","article-title":"Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes","volume":"123","author":"Ly","year":"2013","journal-title":"J Clin Investig"},{"key":"10.1016\/j.neurot.2025.e00624_bib133","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejmech.2015.10.018","article-title":"Pivotal role of glycogen synthase kinase-3: a therapeutic target for Alzheimer's disease","volume":"107","author":"Maqbool","year":"2016","journal-title":"Eur J Med Chem"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00624_bib134","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14728222.2018.1526925","article-title":"Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging","volume":"22","author":"Duda","year":"2018","journal-title":"Expert Opin Ther Targets"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00624_bib135","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-15-2240","article-title":"Molecular pathways: revisiting glycogen synthase kinase-3beta as a target for the treatment of cancer","volume":"23","author":"Walz","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib136","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bbrc.2003.11.014","article-title":"Divergent roles of GSK3 and CDK5 in APP processing","volume":"312","author":"Ryder","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib137","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo","volume":"35","author":"Sereno","year":"2009","journal-title":"Neurobiol Dis"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00624_bib138","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.bmcl.2015.01.005","article-title":"Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3beta inhibitors for Alzheimer's disease","volume":"25","author":"Fukunaga","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib139","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1021\/acs.jmedchem.5b01550","article-title":"Discovery of isonicotinamides as highly selective, brain penetrable, and orally active glycogen synthase kinase-3 inhibitors","volume":"59","author":"Luo","year":"2016","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.neurot.2025.e00624_bib140","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1021\/jm201724m","article-title":"Discovery of novel potent and highly selective glycogen synthase kinase-3beta (GSK3beta) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines","volume":"55","author":"Berg","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.neurot.2025.e00624_bib141","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/935403","article-title":"Andrographolide stimulates neurogenesis in the adult Hippocampus","volume":"2015","author":"Varela-Nallar","year":"2015","journal-title":"Neural Plast"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib142","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54557-5","article-title":"The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents","volume":"9","author":"Griebel","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib143","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00213-018-5108-0","article-title":"Chronic low dose of AM404 ameliorates the cognitive impairment and pathological features in hyperglycemic 3xTg-AD mice","volume":"236","author":"Huang","year":"2019","journal-title":"Psychopharmacology (Berl)."},{"issue":"33","key":"10.1016\/j.neurot.2025.e00624_bib144","doi-asserted-by":"crossref","first-page":"9601","DOI":"10.1002\/anie.201603797","article-title":"Discovery of a highly selective glycogen synthase kinase-3 inhibitor (PF-04802367) that modulates tau phosphorylation in the brain: translation for PET neuroimaging","volume":"55","author":"Liang","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib145","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3233\/JAD-190256","article-title":"Efficacy and safety of glycogen synthase kinase 3 inhibitors for alzheimer's disease: a systematic review and meta-analysis","volume":"69","author":"Matsunaga","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib146","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56461-4","article-title":"9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer","volume":"9","author":"Kuroki","year":"2019","journal-title":"Sci Rep"},{"issue":"41","key":"10.1016\/j.neurot.2025.e00624_bib147","doi-asserted-by":"crossref","first-page":"26551","DOI":"10.1021\/acsomega.0c03302","article-title":"Machine learning for discovery of GSK3beta inhibitors","volume":"5","author":"Vignaux","year":"2020","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib148","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1021\/acschemneuro.4c00725","article-title":"Discovery of dual targeting GSK-3beta\/HIV-1 reverse transcriptase inhibitors as neuroprotective antiviral agents","volume":"16","author":"Jones","year":"2025","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib149","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1152\/physrev.00052.2017","article-title":"The role of voltage-gated sodium channels in pain signaling","volume":"99","author":"Bennett","year":"2019","journal-title":"Physiol Rev"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00624_bib150","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00424-018-2189-x","article-title":"Loss-of-function of Nav1.8\/D1639N linked to human pain can be rescued by lidocaine","volume":"470","author":"Kaluza","year":"2018","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.neurot.2025.e00624_bib151","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fmed.2018.00324","article-title":"Homozygosity for the SCN10A polymorphism rs6795970 is associated with hypoalgesic inflammatory bowel disease phenotype","volume":"5","author":"Gonzalez-Lopez","year":"2018","journal-title":"Front Med"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib153","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/pr.57.4.5","article-title":"International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels","volume":"57","author":"Catterall","year":"2005","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib154","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/geno.1998.5735","article-title":"Evolution and diversity of mammalian sodium channel genes","volume":"57","author":"Plummer","year":"1999","journal-title":"Genomics"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3959(98)00120-1","article-title":"A tetrodotoxin-resistant voltage-gated sodium channel from human dorsal root ganglia, hPN3\/SCN10A","volume":"78","author":"Rabert","year":"1998","journal-title":"Pain"},{"issue":"6562","key":"10.1016\/j.neurot.2025.e00624_bib156","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/379257a0","article-title":"A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons","volume":"379","author":"Akopian","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2025.e00624_bib157","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/9195","article-title":"The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways","volume":"2","author":"Akopian","year":"1999","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib158","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pain.2007.07.026","article-title":"The roles of sodium channels in nociception: implications for mechanisms of pain","volume":"131","author":"Cummins","year":"2007","journal-title":"Pain"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00624_bib159","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/cmdc.201200298","article-title":"Advances in targeting voltage-gated sodium channels with small molecules","volume":"7","author":"Nardi","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.neurot.2025.e00624_bib160","unstructured":"Anon. PF-06305591 [Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&amp;term=PF06305591&amp;cntry1=&amp;state1=&amp;SearchAll=Search+all+studies&amp;recrs=."},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib161","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective Na(V)1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00624_bib162","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of Na(V)1.8 with VX-548 for acute pain","volume":"389","author":"Jones","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib163","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuron.2016.02.021","article-title":"Psychiatric risk gene transcription factor 4 regulates intrinsic excitability of prefrontal neurons via repression of SCN10a and KCNQ1","volume":"90","author":"Rannals","year":"2016","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00624_bib164","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11095-019-2671-y","article-title":"Repurposing approved drugs as inhibitors of K(v)7.1 and Na(v)1.8 to treat Pitt Hopkins syndrome","volume":"36","author":"Ekins","year":"2019","journal-title":"Pharm Res"},{"key":"10.1016\/j.neurot.2025.e00624_bib165","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Cont Clin Trial Comm."},{"issue":"5","key":"10.1016\/j.neurot.2025.e00624_bib166","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41563-019-0332-5","article-title":"Opportunities and challenges using artificial intelligence in ADME\/Tox","volume":"18","author":"Bhhatarai","year":"2019","journal-title":"Nat Mater"},{"key":"10.1016\/j.neurot.2025.e00624_bib167","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1239159","article-title":"\u03bc-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges","volume":"14","author":"Salinsky","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib168","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1038\/s41598-022-08085-4","article-title":"Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00624_bib169","doi-asserted-by":"crossref","DOI":"10.1177\/26331055211033847","article-title":"Engineering safer psychedelics for treating addiction","volume":"16","author":"Peters","year":"2021","journal-title":"Neuroscience Insights"},{"key":"10.1016\/j.neurot.2025.e00624_bib170","article-title":"Ayahuasca, an ancient substance with traditional and contemporary use in neuropsychiatry and neuroscience","author":"Dos Santos","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00624_bib171","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.cell.2021.03.043","article-title":"Psychedelic-inspired drug discovery using an engineered biosensor","volume":"184","author":"Dong","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2025.e00624_bib172","series-title":"PIHKAL: a chemical love story","author":"Shulgin","year":"1990"},{"key":"10.1016\/j.neurot.2025.e00624_bib173","series-title":"TIHKAL: the continuation","author":"Shulgin","year":"2002"},{"issue":"16","key":"10.1016\/j.neurot.2025.e00624_bib174","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1021\/acschemneuro.4c00405","article-title":"Predicting the hallucinogenic potential of molecules using artificial intelligence","volume":"15","author":"Urbina","year":"2024","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib175","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/acs.chemrev.3c00375","article-title":"Serotonin 2A receptor (5-HT(2A)R) agonists: psychedelics and non-hallucinogenic analogues as emerging antidepressants","volume":"124","author":"Duan","year":"2024","journal-title":"Chem Rev"},{"key":"10.1016\/j.neurot.2025.e00624_bib176","series-title":"Adverse outcome pathway and machine learning to predict drug induced seizure liability","author":"Lane","year":"2025"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00624_bib177","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.tiv.2011.05.015","article-title":"Rapid and accurate assessment of seizure liability of drugs by using an optimal support vector machine method","volume":"25","author":"Zhang","year":"2011","journal-title":"Toxicol Vitro"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib178","first-page":"560","article-title":"Assessment of a 3D neural spheroid model to detect pharmaceutical-induced neurotoxicity","volume":"39","author":"Wang","year":"2022","journal-title":"ALTEX"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib179","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/s41598-022-05697-8","article-title":"Raster plots machine learning to predict the seizure liability of drugs and to identify drugs","volume":"12","author":"Matsuda","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00624_bib180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.taap.2018.03.028","article-title":"Do in vitro assays in rat primary neurons predict drug-induced seizure liability in humans?","volume":"346","author":"Kreir","year":"2018","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib181","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/toxsci\/kfy029","article-title":"In vitro screening for seizure liability using microelectrode array technology","volume":"163","author":"Bradley","year":"2018","journal-title":"Toxicol Sci"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib182","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jphs.2017.01.003","article-title":"Machine learning-based prediction of adverse drug effects: an example of seizure-inducing compounds","volume":"133","author":"Gao","year":"2017","journal-title":"J Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib183","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2131\/jts.39.579","article-title":"Establishment of a novel experimental protocol for drug-induced seizure liability screening based on a locomotor activity assay in zebrafish","volume":"39","author":"Koseki","year":"2014","journal-title":"J Toxicol Sci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib184","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.vascn.2008.01.004","article-title":"Validation of a larval zebrafish locomotor assay for assessing the seizure liability of early-stage development drugs","volume":"57","author":"Winter","year":"2008","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.neurot.2025.e00624_bib185","series-title":"\"Identifying seizure-inducing biological targets: a collaborative approach using AOP networks, In Vitro assays, and computational tools\", the toxicologist, a supplement to toxicological sciences, Abstract #1045","year":"2024"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00624_bib186","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood-brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00624_bib187","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000594","article-title":"Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR","volume":"5","author":"Ekins","year":"2009","journal-title":"PLoS Comput Biol"},{"issue":"14","key":"10.1016\/j.neurot.2025.e00624_bib188","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1021\/acs.jmedchem.6b01469","article-title":"CNS physicochemical property space shaped by a diverse set of molecules with experimentally determined exposure in the mouse brain","volume":"60","author":"Rankovic","year":"2017","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib189","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1021\/acs.jmedchem.8b01388","article-title":"Retraction of \"CNS physicochemical property space shaped by a diverse set of molecules with experimentally determined exposure in the mouse brain\"","volume":"62","author":"Rankovic","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.neurot.2025.e00624_bib190","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jmgm.2017.05.021","article-title":"In silico modeling on ADME properties of natural products: classification models for blood-brain barrier permeability, its application to traditional Chinese medicine and in vitro experimental validation","volume":"75","author":"Zhang","year":"2017","journal-title":"J Mol Graph Model"},{"key":"10.1016\/j.neurot.2025.e00624_bib191","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/292683","article-title":"A genetic algorithm based support vector machine model for blood-brain barrier penetration prediction","volume":"2015","author":"Zhang","year":"2015","journal-title":"BioMed Res Int"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib192","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1208\/s12248-018-0215-8","article-title":"Improved prediction of blood-brain barrier permeability through machine learning with combined use of molecular property-based descriptors and fingerprints","volume":"20","author":"Yuan","year":"2018","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib193","doi-asserted-by":"crossref","DOI":"10.3390\/md17020081","article-title":"Predicting Blood(-)Brain barrier permeability of marine-derived kinase inhibitors using ensemble classifiers reveals potential hits for neurodegenerative disorders","volume":"17","author":"Plisson","year":"2019","journal-title":"Mar Drugs"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib194","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1038\/s41598-019-44773-4","article-title":"Improved classification of blood-brain-barrier drugs using deep learning","volume":"9","author":"Miao","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00624_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2020.107377","article-title":"A Recurrent Neural Network model to predict blood-brain barrier permeability","volume":"89","author":"Alsenan","year":"2020","journal-title":"Comput Biol Chem"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00624_bib196","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/bioinformatics\/btaa918","article-title":"LightBBB: computational prediction model of blood-brain-barrier penetration based on LightGBM","volume":"37","author":"Shaker","year":"2021","journal-title":"Bioinformatics"},{"issue":"8-9","key":"10.1016\/j.neurot.2025.e00624_bib197","doi-asserted-by":"crossref","DOI":"10.1002\/minf.201800164","article-title":"Finding needles in a Haystack: determining key molecular descriptors associated with the blood-brain barrier entry of chemical compounds using machine learning","volume":"38","author":"Majumdar","year":"2019","journal-title":"Mol Inform"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00624_bib198","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem Neurosci"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00624_bib199","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central nervous system multiparameter optimization desirability: application in drug discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem Neurosci"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00624_bib200","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1021\/acschemneuro.1c00265","article-title":"Comparing the Pfizer central nervous system multiparameter optimization calculator and a BBB machine learning model","volume":"12","author":"Urbina","year":"2021","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib201","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/med.21764","article-title":"Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: state-of-the-arts and future directions","volume":"41","author":"Vatansever","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.neurot.2025.e00624_bib202","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26726","article-title":"Systematic integration of biomedical knowledge prioritizes drugs for repurposing","volume":"6","author":"Himmelstein","year":"2017","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41398-020-0827-5","article-title":"Drug repositioning for psychiatric and neurological disorders through a network medicine approach","volume":"10","author":"Luscher Dias","year":"2020","journal-title":"Transl Psychiatry"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00624_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111717","article-title":"Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease","volume":"41","author":"Xu","year":"2022","journal-title":"Cell Rep"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00624_bib205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512339","article-title":"Literature-based discovery predicts antihistamines are a promising repurposed adjuvant therapy for Parkinson's disease","volume":"24","author":"Tandra","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00624_bib206","doi-asserted-by":"crossref","DOI":"10.3390\/biom14101330","article-title":"A survey on computational methods in drug discovery for neurodegenerative diseases","volume":"14","author":"Vicidomini","year":"2024","journal-title":"Biomolecules"},{"issue":"16","key":"10.1016\/j.neurot.2025.e00624_bib207","doi-asserted-by":"crossref","first-page":"8736","DOI":"10.1021\/jacs.2c13467","article-title":"Generative models as an emerging paradigm in the chemical sciences","volume":"145","author":"Anstine","year":"2023","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib208","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13321-017-0235-x","article-title":"Molecular de-novo design through deep reinforcement learning","volume":"9","author":"Olivecrona","year":"2017","journal-title":"J Cheminf"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib209","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/acscentsci.7b00512","article-title":"Generating focused molecule libraries for drug discovery with recurrent neural networks","volume":"4","author":"Segler","year":"2018","journal-title":"ACS Cent Sci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13321-019-0397-9","article-title":"A de novo molecular generation method using latent vector based generative adversarial network","volume":"11","author":"Prykhodko","year":"2019","journal-title":"J Cheminf"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib211","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/acscentsci.7b00572","article-title":"Automatic chemical design using a data-driven continuous representation of molecules","volume":"4","author":"Gomez-Bombarelli","year":"2018","journal-title":"ACS Cent Sci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib212","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1021\/acs.jcim.1c01545","article-title":"Analysis of training and seed bias in small molecules generated with a conditional graph-based variational autoencoder horizontal line insights for practical AI-driven molecule generation","volume":"62","author":"Kang","year":"2022","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.neurot.2025.e00624_bib213","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1162\/neco.1997.9.8.1735","article-title":"Long short-term memory","volume":"9","author":"Hochreiter","year":"1997","journal-title":"Neural Comput"},{"issue":"1-2","key":"10.1016\/j.neurot.2025.e00624_bib214","doi-asserted-by":"crossref","DOI":"10.1002\/minf.201700123","article-title":"Application of generative autoencoder in de novo molecular design","volume":"37","author":"Blaschke","year":"2018","journal-title":"Mol Inform"},{"key":"10.1016\/j.neurot.2025.e00624_bib215","author":"Sanchez-Lengeling"},{"issue":"34","key":"10.1016\/j.neurot.2025.e00624_bib216","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1039\/C9SC01928F","article-title":"Efficient multi-objective molecular optimization in a continuous latent space","volume":"10","author":"Winter","year":"2019","journal-title":"Chem Sci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib217","article-title":"Self-referencing embedded strings (SELFIES): a 100% robust molecular string representation","volume":"1","author":"Krenn","year":"2020","journal-title":"Mach Learn: Sci Technol"},{"key":"10.1016\/j.neurot.2025.e00624_bib218","unstructured":"Jin W, Barzilay R, Jaakola T. Junction tree variational autoencoder for molecular graph generation 2019 [Available from: https:\/\/arxiv.org\/pdf\/1802.04364.pdf."},{"key":"10.1016\/j.neurot.2025.e00624_bib219","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13321-019-0404-1","article-title":"Mol-CycleGAN: a generative model for molecular optimization","volume":"12","author":"Maziarka","year":"2020","journal-title":"J Cheminf"},{"issue":"1-2","key":"10.1016\/j.neurot.2025.e00624_bib220","article-title":"Erratum: generative recurrent networks for de novo drug design","volume":"37","author":"Gupta","year":"2018","journal-title":"Mol Inform"},{"key":"10.1016\/j.neurot.2025.e00624_bib221","unstructured":"Bjerrum EJ, Threlfall R. Molecular generation with recurrent neural networks (RNNs). arXiv. 2017;1705.04612."},{"issue":"9","key":"10.1016\/j.neurot.2025.e00624_bib222","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41587-019-0224-x","article-title":"Deep learning enables rapid identification of potent DDR1 kinase inhibitors","volume":"37","author":"Zhavoronkov","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00624_bib223","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1021\/acs.molpharmaceut.7b01137","article-title":"Adversarial Threshold Neural Computer for Molecular de Novo Design","volume":"15","author":"Putin","year":"2018","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00624_bib224","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1012229","article-title":"MTMol-GPT: de novo multi-target molecular generation with transformer-based generative adversarial imitation learning","volume":"20","author":"Ai","year":"2024","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib225","article-title":"A novel framework based on explainable AI and genetic algorithms for designing neurological medicines","volume":"14","author":"Singh","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00624_bib226","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41589-024-01580-x","article-title":"Discovery of potent inhibitors of alpha-synuclein aggregation using structure-based iterative learning","volume":"20","author":"Horne","year":"2024","journal-title":"Nat Chem Biol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00624_bib227","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23081963","article-title":"Evolution of in silico strategies for protein-protein interaction drug discovery","volume":"23","author":"Macalino","year":"2018","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00624_bib228","article-title":"Artificial intelligence and machine learning in neuroregeneration: a systematic review","volume":"16","author":"Mulpuri","year":"2024","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib229","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3390\/neurolint16040060","article-title":"Artificial intelligence as a replacement for animal experiments in neurology: potential, progress, and challenges","volume":"16","author":"Rudroff","year":"2024","journal-title":"Neurol Int"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0315394","article-title":"Distinguishing classes of neuroactive drugs based on computational physicochemical properties and experimental phenotypic profiling in planarians","volume":"20","author":"Ireland","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2025.e00624_bib231","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127930","article-title":"Development of an a priori computational approach for brain uptake of compounds in an insect model system","volume":"40","author":"Geldenhuys","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00624_bib232","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/brain\/awab108","article-title":"Towards realizing the vision of precision medicine: AI based prediction of clinical drug response","volume":"144","author":"de Jong","year":"2021","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib233","article-title":"Data-driven discovery of associations between prescribed drugs and dementia risk: a systematic review","volume":"11","author":"Underwood","year":"2025","journal-title":"Alzheimer's Dement"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00624_bib234","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1002\/alz.13428","article-title":"Artificial intelligence for dementia drug discovery and trials optimization","volume":"19","author":"Doherty","year":"2023","journal-title":"Alzheimer's Dement"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00524","article-title":"Using artificial intelligence to optimize anti-seizure treatment and EEG-guided decisions in severe brain injury","volume":"22","author":"Akras","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib236","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41467-021-21330-0","article-title":"Machine learning identifies candidates for drug repurposing in Alzheimer's disease","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2025.e00624_bib237","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fnins.2011.00103","article-title":"Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms","volume":"5","author":"Roberds","year":"2011","journal-title":"Front Neurosci"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00624_bib238","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci14080770","article-title":"Real-time analysis of neuronal cell cultures for CNS drug discovery","volume":"14","author":"Akere","year":"2024","journal-title":"Brain Sci"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00624_bib239","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110875","article-title":"Few-shot meta-learning applied to whole brain activity maps improves systems neuropharmacology and drug discovery","volume":"27","author":"Luo","year":"2024","journal-title":"iScience"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00624_bib240","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41591-024-03224-y","article-title":"High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity","volume":"30","author":"Lee","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00624_bib241","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/17460441.2022.2072288","article-title":"Reinforcement learning for systems pharmacology-oriented and personalized drug design","volume":"17","author":"Tan","year":"2022","journal-title":"Expet Opin Drug Discov"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib242","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae690","article-title":"STNGS: a deep scaffold learning-driven generation and screening framework for discovering potential novel psychoactive substances","volume":"26","author":"Liu","year":"2024","journal-title":"Briefings Bioinf"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib243","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s42256-022-00465-9","article-title":"Dual use of artificial intelligence-powered drug discovery","volume":"4","author":"Urbina","year":"2022","journal-title":"Nat Mach Intell"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib244","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/ajad.12862","article-title":"Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment","volume":"28","author":"Kosten","year":"2019","journal-title":"Am J Addict"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib245","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoact Drugs"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib246","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2017.19.3\/tcicero","article-title":"The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse","volume":"19","author":"Cicero","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib247","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/pr.114.009514","article-title":"Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder","volume":"67","author":"Howell","year":"2015","journal-title":"Pharmacol Rev"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00624_bib248","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1523\/JNEUROSCI.4901-04.2006","article-title":"Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool","volume":"26","author":"Venton","year":"2006","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib249","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00702-018-1957-2","article-title":"Dopamine and addiction: what have we learned from 40 years of research","volume":"126","author":"Solinas","year":"2019","journal-title":"J Neural Transm"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00624_bib250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158106","article-title":"Altered accumbal dopamine terminal dynamics following chronic heroin self-administration","volume":"23","author":"George","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"39","key":"10.1016\/j.neurot.2025.e00624_bib251","doi-asserted-by":"crossref","first-page":"16446","DOI":"10.1073\/pnas.1105418108","article-title":"Neuronal circuits underlying acute morphine action on dopamine neurons","volume":"108","author":"Jalabert","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib252","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/s41467-023-37045-3","article-title":"Cocaine induces locomotor sensitization through a dopamine-dependent VTA-mPFC-FrA cortico-cortical pathway in male mice","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib253","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission","volume":"113","author":"Alex","year":"2007","journal-title":"Pharmacol Ther"},{"issue":"2-3","key":"10.1016\/j.neurot.2025.e00624_bib254","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00213-010-2029-y","article-title":"Presynaptic control of serotonin on striatal dopamine function","volume":"213","author":"Navailles","year":"2011","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.neurot.2025.e00624_bib255","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518800508","article-title":"Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics","volume":"12","author":"Olson","year":"2018","journal-title":"J Exp Neurosci"},{"issue":"7842","key":"10.1016\/j.neurot.2025.e00624_bib256","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00624_bib257","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/dneu.20774","article-title":"Brain-derived neurotrophic factor and the development of structural neuronal connectivity","volume":"70","author":"Cohen-Cory","year":"2010","journal-title":"Dev Neurobiol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00624_bib258","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0269881114568040","article-title":"Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?","volume":"29","author":"Maji\u0107","year":"2015","journal-title":"J Psychopharmacol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00624_bib259","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib260","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cell.2018.01.001","article-title":"5-HT(2C) receptor structures reveal the structural basis of GPCR polypharmacology","volume":"172","author":"Peng","year":"2018","journal-title":"Cell."},{"issue":"22","key":"10.1016\/j.neurot.2025.e00624_bib261","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1111\/bph.16233","article-title":"Molecular and structural insights into the 5-HT(2C) receptor as a therapeutic target for substance use disorders","volume":"181","author":"Ubhayarathna","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00624_bib262","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s43440-022-00428-2","article-title":"Evaluation of the 5-HT(2C) receptor drugs RO 60-0175, WAY 161503 and mirtazepine in a preclinical model of comorbidity of depression and cocaine addiction","volume":"75","author":"Jastrzebska","year":"2023","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.neurot.2025.e00624_bib263","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.neuropharm.2015.09.031","article-title":"Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice","volume":"101","author":"Zhang","year":"2016","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00624_bib264","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.npp.1301548","article-title":"Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism","volume":"33","author":"Lanteri","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"1-2","key":"10.1016\/j.neurot.2025.e00624_bib265","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0006-8993(97)01267-5","article-title":"Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens","volume":"781","author":"Willins","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.neurot.2025.e00624_bib266","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neulet.2015.09.013","article-title":"Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice","volume":"607","author":"Wu","year":"2015","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurot.2025.e00624_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107859","article-title":"Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder","volume":"208","author":"Brandt","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.neurot.2025.e00624_bib268","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108482","article-title":"Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: a pilot, placebo-controlled randomized trial","volume":"219","author":"Levin","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib269","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14659891.2023.2202760","article-title":"Open label pilot of lorcaserin (a serotonin 2C-receptor agonist) for cannabis use disorder","volume":"29","author":"Brezing","year":"2024","journal-title":"J Subst Use"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00624_bib270","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12993","article-title":"5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers","volume":"26","author":"Arout","year":"2021","journal-title":"Addict Biol"},{"issue":"22","key":"10.1016\/j.neurot.2025.e00624_bib271","doi-asserted-by":"crossref","first-page":"18699","DOI":"10.1021\/acsomega.2c01404","article-title":"Integrating generative molecular design, automated analog designer, and synthetic viability prediction","volume":"7","author":"Urbina","year":"2022","journal-title":"ACS Omega"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00624_bib272","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1021\/acscentsci.8b00747","article-title":"Canvass: a crowd-sourced, natural-product screening library for exploring biological space","volume":"4","author":"Kearney","year":"2018","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.neurot.2025.e00624_bib273","series-title":"An introduction to generative Drug Discovery","author":"Ekins","year":"2025"},{"key":"10.1016\/j.neurot.2025.e00624_bib274","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drudis.2011.02.016","article-title":"In silico repositioning of approved drugs for rare and neglected diseases","volume":"16","author":"Ekins","year":"2011","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00624_bib275","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.drudis.2021.10.014","article-title":"Knowledge-based approaches to drug discovery for rare diseases","volume":"27","author":"Alves","year":"2022","journal-title":"Drug Discov Today"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00624_bib276","doi-asserted-by":"crossref","first-page":"11870","DOI":"10.1021\/acsomega.3c09607","article-title":"Identification of new modulators and inhibitors of palmitoyl-protein thioesterase 1 for CLN1 batten disease and cancer","volume":"9","author":"Puhl","year":"2024","journal-title":"ACS Omega"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:01:48Z","timestamp":1755090108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":274,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1878747925001023"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00624","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applications of artificial intelligence in drug discovery for neurological diseases","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Collaborations Pharmaceuticals, inc. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00624"}}